News & Insights
Pharma Commercialisation Services Update – September 2022
Welcome to our latest update on the outsourced Pharma Commercialisation Services sector. As well as our usual update on M&A activity, this report takes a deep dive into one of the biggest challenges businesses are currently facing – the War for Talent. A phrase first coined by McKinsey in the late ’90s but one that […]
Pharma Licensing: the why, the how and a few things to get right!
Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP). IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios. A pharma licensing deal […]
We are joining forces with Canaccord Genuity
We are very excited to share that we have agreed to join forces with Canaccord Genuity – a leading full-service investment bank serving growth companies in the middle market. This is an important milestone in our journey and we wanted to update you on why we’ve taken this decision and what it means for you. […]
Transforming healthcare with real-world evidence (RWE)
The healthcare industry experienced a revolutionary shift when it switched from practising medicine as an art to evidence-based medicine, which is based on relatively simple randomised clinical trials to determine which treatment option was safe and effective. Through the years, evidence-based medicine became the gold standard for clinical development. However, this method has become less […]
BIO International in San Diego: Sunny with scattered economic clouds
The biopharma universe gathered in San Diego last week for the first face to face BIO International conference in three years. Turn-out was good but below the get-together in Philadelphia in 2019. That one topped out above 17,000 attendees according to the BIO website; whisper numbers this time around were in the region of 12,000. I […]
Biotech funding in a risk-off climate – does upstream trouble loom for pharma services providers?
Biotech funding is the key driver of innovation in the pharmaceutical industry and is essential in supporting the healthcare ecosystem. More than 80% of drugs marketed by large pharmaceutical companies were discovered and initially developed by biotechs1. Biotech companies also discovered more than 60% of FDA-approved “priority” drugs, which treat life-threatening conditions and offer significant […]
Crossrail opens – a big day for travellers to and workers in London
At Results Healthcare we execute transactions around the world, with active projects in North America, Europe and Asia Pacific, so we see ourselves as a global organisation with offices and employees in London and New York, so a blog on transport in London might seem oddly parochial, but the opening of Crossrail, or the Elizabeth […]
DCAT’s Back / Back at DCAT
For the first time in forever it felt like the good old days were back in midtown Manhattan at everyone’s favourite pharma supply chain conference The hotels. The meetings. The dinners. Walking up and down Lexington Avenue and bumping into friends and colleagues. It was all happening again at DCAT last week in New York. […]
The growing impact of Environmental, Social, and Governance (“ESG”) on pharmaceutical supply chains.
The Russian invasion of Ukraine has been touted as the final nail in the coffin of globalisation, confirming the nationalisation of key industries and products. With respect to pharmaceutical manufacturing, this is accelerating a trend which has been ongoing for 10 years, the repatriation of drug manufacturing from Asia to the US and Europe has […]
We add value by understanding our sectors inside-out, and we release regular industry research and reports on key trends in the technology and healthcare sectors. Fill out the form to start receiving alerts when we publish new content or to follow our latest deals, upcoming events and company updates.